TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04296916
Drug: IOP lowering eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops.
Study: NCT01290978
Drug: DuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
Study: NCT01095978
Drug: Clarithromycin (Klacid SR)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Klacid SR in a dose of 1000 mg once daily
Study: NCT03088709
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV medication given for prevention of graft versus host disease.
Study: NCT00650195
Drug: Zaroloxyn® Tablets 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg, single dose fasting
Study: NCT01904864
Drug: elemental iron (NovaFerrum®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
Study: NCT01904864
Drug: elemental iron (Ferrous Sulfate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
Study: NCT01260883
Drug: Ketorolac Tromethamine 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
Study: NCT03793725
Drug: SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Antibody
Study: NCT00191282
Drug: Human insulin isophane suspension (NPH)
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \>8.0%
Study: NCT00191282
Drug: Human insulin isophane suspension
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
Study: NCT00191282
Drug: Human insulin 30/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \>8.0%.
Study: NCT03152955
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
Study: NCT01498822
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
Study: NCT04678921
Drug: TJ210001
Approvals — FDA: no, EMA: no, PMDA: no
Description: human anti-C5aR monoclonal antibody
Study: NCT02565277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00881491
Drug: Double Antibiotic Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
Study: NCT00881491
Drug: Triple Antibiotic Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
Study: NCT00352092
Drug: calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02913664
Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
Normalized name: Angiotensin II receptor blockers (ARBs) and calcium channel blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)
Study: NCT00242372
Drug: Insulin at least 30 units/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05125575
Drug: Glucophage® XR 1000 mg Prolonged Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the Reference (R) product was administered orally with 240 mL of water.
Study: NCT00361439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs in each nostril once daily of nasal spray
Study: NCT02809105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily
Study: NCT01684098
Drug: Tc 99m EC20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03204955
Drug: PlasmaLyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
Study: NCT00910962
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
Study: NCT00910962
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
Study: NCT00910962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02461719
Drug: CYPORIN N EYE DROPS 0.05%(TJCS eye drop)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop twice/day for 12 weeks to both eyes.
Study: NCT02805426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05199623
Drug: tailored Guizhi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
Study: NCT03465774
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive via IPC
Study: NCT03595930
Drug: Arnuity
Normalized name: Arnuity
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
Study: NCT02836236
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF 25 mg tablet administered orally once daily
Study: NCT02836236
Drug: TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF placebo tablet administered orally once daily
Study: NCT00084370
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
Study: NCT02836236
Drug: TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF placebo tablet administered orally once daily
Study: NCT01106677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
Study: NCT01163214
Drug: Nerve Block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
Study: NCT04849286
Drug: HTL0016878
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00161239
Drug: Doxil, Methotrexate, L-Asparaginase, Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01119898
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Study: NCT03337945
Drug: Basel phenotyping cocktail capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling
Study: NCT03360916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo tablet by mouth every day for 12 weeks.
Study: NCT02796066
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied once a day
Study: NCT02796066
Drug: TSN2898
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied once a day
Study: NCT03397329
Drug: AG-348 Sequence B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)
Study: NCT01159236
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 for 4 courses (once every 7 days)
Study: NCT01159236
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
Study: NCT01159236
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
Study: NCT02311413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Study: NCT01466569
Drug: AbGn-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
Study: NCT01466569
Drug: AbGn-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Study: NCT02142725
Drug: LT-02
Normalized name: LT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: four times per day
Study: NCT02142725
Drug: LT-02
Normalized name: LT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: two times per day
Study: NCT02142725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: four times per day
Study: NCT00941798
Drug: QMF149 Twisthaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via multi-dose dry-powder inhaler
Study: NCT01689246
Drug: TRx0237 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRx0237 75 mg tablets will be administered twice daily.
Study: NCT01689246
Drug: TRx0237 250 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRx0237 125 mg tablets will be administered twice daily.
Study: NCT01689246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT03724903
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
Study: NCT01248052
Drug: LY2979165
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT01248052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT02381132
Drug: Norco 7.5mg/325
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02381132
Drug: MNK155
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01857999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02222350
Drug: 75mg DS-8500a tablet
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02222350
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03333824
Drug: CYP1A2 (caffeine)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
Study: NCT03834766
Drug: AMPH ER Tab 5, 10, 15 and 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine
Study: NCT03333824
Drug: Wee-1 kinase inhibitor AZD1775
Normalized name: PROTEIN KINASE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study: NCT03933618
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00438607
Drug: BIIB014
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
Study: NCT00438607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo for MTD or MTD-1
Study: NCT01249638
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
Study: NCT02395133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
Study: NCT04444635
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous fentanyl infusion throughout the surgical procedure.
Study: NCT01249638
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
Study: NCT02671266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
Study: NCT02165332
Drug: Part 1: SAD RO7033877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02165332
Drug: Part 1: SAD placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02165332
Drug: Part 2: Treatment A, RO7033877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose RO7033877 and moxifloxacin placebo
Study: NCT02165332
Drug: Part 2: Treatment B, RO7033877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose RO7033877 and moxifloxacin placebo
Study: NCT02310022
Drug: Drug Omega 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g (4 capsules) once a day, administered with food
Study: NCT02310022
Drug: Drug Omega-3 Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g (4 capsules) once a day, administered with food
Study: NCT00110370
Drug: Lispro Mixture Therapy
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01738880
Drug: CVP
Normalized name: CVP Manometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
Study: NCT02822625
Drug: QUTENZA®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01018225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill, once a day, for six weeks
Study: NCT02484170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
Study: NCT01041846
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
Study: NCT02228239
Drug: Placebo (Matched to Mirtazapine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
Study: NCT03315130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection
Study: NCT03133299
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone for four months
Study: NCT02091596
Drug: PluroGel N
Normalized name: PLUROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT02091596
Drug: PluroGel
Normalized name: PLUROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: PluroGel Vehicle Placebo Comparator
Study: NCT00681109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: custom eye drop to be applied three times a day in both eyes for three months
Study: NCT04432714
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 10 mg/m2/day CI24h d1-d4
Study: NCT04432714
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2/day IV d5
Study: NCT00387140
Drug: MK2295
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01915667
Drug: 200 mg GLPG0634 as capsules, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
Study: NCT01915667
Drug: 200 mg GLPG0634 as tablets, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
Study: NCT01915667
Drug: 200 mg GLPG0634 as tablets, fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 200 mg GLPG0634 given as tablets in fed condition
Study: NCT02350686
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
Study: NCT00687297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03829618
Drug: Nebuliser Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
Study: NCT00893009
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice a day
Study: NCT00893009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03711279
Drug: ADM plus IFO or IFO alone
Normalized name: Sooth-It Plus Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
Study: NCT01913431
Drug: Baracle Tab.®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01913431
Drug: Baraclude Tab.®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04303026
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg IV infusion
Study: NCT04303026
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group. Saline 0.9% 100 ml infusion
Study: NCT00405522
Drug: Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Study: NCT00405522
Drug: Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Study: NCT03740555
Drug: HNC042 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
Study: NCT03740555
Drug: Placebo multiple ascending doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
Study: NCT03937440
Drug: Deep neuromuscular block with 'rocunium®'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
Study: NCT03691441
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
Study: NCT03937440
Drug: Moderate neuromuscular block with 'rocunium®'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.